GLP-1 drugs for people with diabetes on dialysis
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if a type 2 diabetes medication called a GLP-1 receptor agonist (like Ozempic) is safe and effective for people on dialysis. It may help manage blood sugar and improve health outcomes for those with kidney failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been on dialysis (hemodialysis or peritoneal dialysis) for at least 3 months
- You have type 2 diabetes (you take pills or insulin for it)
- You haven't taken a GLP-1 drug (like Ozempic or Trulicity) in the last month
- You and your family don't have a history of certain rare thyroid or pancreas problems
- You are not pregnant and don't plan to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.